Hepatocellular carcinoma
Conditions
Interventions
Intervention group:Intravenous infusion of lidocaine
Sponsors
Affiliated Hospital of North Sichuan Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients with primary diagnosis of liver cancer; 2. Aged 18-65 years; 3. ASA I-III grade; 4. BMI 18-30 kg/m2; 5. Plan to accept elective laparoscopic surgery.
Exclusion criteria
Exclusion criteria: 1. Severe hepatic and renal insufficiency (total bilirubin > 1.46 mg/dl; glomerular filtration rate < 30 ml/min/1.73m2; end-stage renal disease); 2. Severe heart disease (severe heart block, sinus bradycardia, Adams-stokes syndrome, preexcitation syndrome, etc.); 3. People allergic to lidocaine; 4. Long term use of cimetidine beta Receptor blockers and other drugs that affect the metabolism of lidocaine; 5. Ideal Body Weight (IBW) < 40 kg; 6. Have a history of epilepsy; 7. Those who are participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma concentration of lidocaine;Plasma concentration of active metabolites of lidocaine;Maximum peak concentration of the drug in plasma (Cmax);Time to reach maximum concentration (Tmax);Terminal elimination half-life (t1/2);Clearance rates;Apparent distribution volume;Area under the curve (AUC) from time zero to infinity;AUC0-t;Single nucleotide polymorphisms of metabolic enzymes CYP1A2 and CYP3A4;Age, gender, height, weight, ideal weight and body mass index;Biochemical indexes such as liver and kidney function before and after operation;Anesthesia time, operation time, hepatic portal block time, hepatic portal block times; | — |
Countries
China
Contacts
Public ContactFaping Tu
Affiliated Hospital of North Sichuan Medical College
Outcome results
None listed